Dynavax Technologies Corporation (NASDAQ:DVAX): Hepatitis B Vaccine Trails Positive Results


Dallas, Texas 10/09/2013 (Financialstrend) – Dynavax Technologies Corporation (NASDAQ:DVAX) is a drug manufacturer. On September 25, Dynavax Technologies announced positive results from its “immunogenicity and safety data” clinic trails for its target vaccine which it has designed to forestall hepatitis B. The company has also indicated that the results from its phase 3 trials of its vaccine target named Heplisav were published in the journal VACCINE.

As part of the clinical trial, healthy adults in the age group of 40 to 70 were administered the target vaccine Heplisav. The results were compared to effects produced by existing hepatitis B vaccines with respect immunogenicity and safety factors. The tests covered 2400 subjects and were spread across U.S and Canada. The results indicated a higher “serprotection” rates in direct comparison to other licensed hepatitis B vaccines which are available in the market. The results were observed on administering smaller doses of the target vaccine spread over a 30 day period.

In the second part of the trail was conducted in Germany and U.S. The target vaccine was tried on 500 patients suffering with chronic kidney disease. These results too were very encouraging. Patients were observed to have developed significantly higher seroprotection in comparison to existing vaccines. These results are getting published in the back drop of June 2013 temporary setback the drug manufacturer had suffered when U.S. Food and Drug Administration had sought additional safety data on tests conducted on Heplisav. In addition to this target vaccine for Hepatitis, the company is also working on two other drug candidates in association with bigger drug manufacturers.

As of close of business on October 8, the shares of the company were trading at $1.21 per share which was 5.4% less compared to its previous day close. At current valuations the stock has a market cap of $221 million.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.